July 21, 2026
The DEA cannabis rescheduling hearing is over. Closing arguments landed Wednesday, July 15, ending a 17-day proceeding that ran at DEA headquarters since June 29 (DEA). Nobody banged a gavel and moved marijuana to Schedule III. What the industry got instead was a calendar, and the calendar is the story.
Chief Administrative Law Judge Derek Julius closed the record and set August 17 as the deadline for parties to file optional post-hearing briefs and transcript corrections (Ground News roundup). After that date, three things happen in order:
The recommendation is advisory. The Administrator can accept it, modify it, or reject it, and the December 2025 executive order that put this proceeding on an expedited track pushes the agency toward finishing rather than stalling (DEA regulatory actions page).
Worth restating, because prospects will get this wrong on sales calls: part of rescheduling already happened. The April 23 order moved FDA-approved marijuana products and state-medical-licensed marijuana into Schedule III, and it took IRS Section 280E off the table for the operators it covers. We walked through that split, and why it turns one dispensary list into two tax brackets, when the hearing opened in June.
The July hearing was about everyone else. Adult-use marijuana and anything outside an FDA approval or state medical license is still Schedule I today, and stays there until a final rule says otherwise.
If Judge Julius's recommendation arrives in the fall and the DEA moves at the pace the executive order demands, a final rule is plausibly a late-2026 or 2027 event. Two consequences for anyone selling into dispensaries:
Adult-use operators are still buying under 280E economics. Their margins stay compressed until a final rule lands, so budget conversations with rec-only shops should assume the current tax math, not the hoped-for one.
The medical side already crossed. A state-medical-licensed operator has had Schedule III treatment since April. Those are the accounts where "we have more room in the budget this year" is a real sentence, and license type is the field that tells you which conversation you're walking into.
None of this is legal or tax advice; operators and vendors making decisions on it should confirm specifics with counsel. But the broad shape is public record: the argument phase is done, the paper phase ends August 17, and the deciding phase has no clock on it.
Did the DEA decide to reschedule marijuana? Not yet. The hearing that ended July 15, 2026 was evidentiary. Judge Julius will issue a recommendation after post-hearing briefs close on August 17; the DEA Administrator makes the final call.
Is any marijuana already Schedule III? Yes. Since the April 23, 2026 order, FDA-approved marijuana products and marijuana sold under qualifying state medical licenses are Schedule III. Adult-use marijuana remains Schedule I.
When would a final rule take effect? No deadline exists. Given the expedited posture and the pending consolidated litigation, late 2026 to 2027 is the realistic window, and court challenges can stretch it.
Which of your prospects already crossed into Schedule III comes down to their license type, and that's a field in every one of our records. See verified, license-checked dispensary contacts across six states, refreshed weekly. Free preview here.
Holden Leads
Holden Leads tracks every licensed dispensary across California, Michigan, Illinois, and Massachusetts — cross-referenced weekly against official state regulatory databases and enriched with phone numbers, emails, websites, and social profiles. Stop manually hunting for contact info. Get the full list today.